Eagle Capital Growth Fund, Inc.
GRFDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 12, 2025 | $0.85 | 2025-11-21 | 2025-11-21 |
| December 19, 2024 | $0.68 | 2024-11-29 | 2024-11-29 |
| December 15, 2023 | $0.35 | 2023-11-22 | 2023-11-24 |
| December 14, 2022 | $0.37 | 2022-11-17 | 2022-11-18 |
| December 23, 2021 | $0.97 | 2021-11-18 | 2021-11-19 |
Dividends Summary
- Consistent Payer: Eagle Capital Growth Fund, Inc. has rewarded shareholders with 28 dividend payments over the past 17 years.
- Total Returned Value: Investors who held GRF shares during this period received a total of $10.54 per share in dividend income.
- Latest Payout: The most recent dividend of $0.85/share was paid 42 days ago, on December 12, 2025.
- Yield & Schedule: GRF currently pays dividends yearly with an annual yield of 7.75%.
- Dividend Growth: Since 2008, the dividend payout has grown by 1983.3%, from $0.04 to $0.85.
Company News
BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo�...
BARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group Corporation (Haier Group) and forged a strategic alliance with Ha...
BARCELONA, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immuno...
BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially celebrated the 50th anniversary of its flagship site in Clayton, N.C., whose production of these essential therapeutics during its existence has saved ...
BARCELLONA, Spagna, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), uno dei principali produttori mondiali di farmaci plasmaderivati e di soluzioni diagnostiche innovative, ha annunciato in data odierna che il suo nuovo Procleix ArboPlex Assay ha ottenuto il marchio CE ai sensi della normativa sulla diagnostica i...
